Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAVO-EP and Pembrolizumab in TNBC
NCT03567720Phase 2Unknown
- Sponsor
- OncoSec Medical
- Start
- Oct 2018
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of tavokinogene telseplasmid in triple-negative breast cancer (TNBC), sponsored by OncoSec Medical. Status: unknown.
02
Drugs
tavokinogene telseplasmid
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03567720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567720.